Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Howard Hughes Medical Institute, Bethesda, Maryland.
Cancer Discov. 2024 Nov 1;14(11):2025-2027. doi: 10.1158/2159-8290.CD-24-1195.
Annual low-dose CT screening of individuals with a smoking history identifies early curable lung tumors and reduces cancer mortality by 20%, yet only a minority of eligible patients undergo such monitoring. Mazzone and colleagues apply a blood-based cfDNA fragmentomic assay as a high-sensitivity/low-specificity pre-screen to help stratify individuals who may benefit most from more definitive low-dose CT imaging. See related article by Mazzone et al., p. 2224.
对有吸烟史的个体进行年度低剂量 CT 筛查可发现早期可治愈的肺癌肿瘤，并将癌症死亡率降低 20%，但只有少数符合条件的患者接受这种监测。Mazzone 及其同事应用一种基于血液的 cfDNA 片段组学检测作为高灵敏度/低特异性的预筛查方法，以帮助分层最有可能从更明确的低剂量 CT 成像中获益的个体。请参阅 Mazzone 等人的相关文章，第 2224 页。
